• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

    3/11/25 9:32:16 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REGN alert in real time by email

    TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Matteo Paz,18, of Pasadena, CA, won the top award of $250,000 in the 2025 Regeneron Science Talent Search, the U.S.'s oldest and most prestigious science and math competition for high school seniors.

    Now in its 84th year, the competition celebrates and rewards young innovators who are applying their Science, Technology, Engineering and Math (STEM) talent and leadership skills to push the boundaries of discovery and address today's pressing challenges.

    Forty finalists, including Matteo, were honored this evening during an award ceremony at the National Building Museum in Washington, D.C, where they were awarded more than $1.8 million in prizes for their groundbreaking research, exceptional problem-solving skills and potential to shape the future of STEM.

    • Matteo Paz, 18, of Pasadena, CA, won first place and $250,000 for designing machine-learning algorithms to efficiently comb through 200 billion entries of raw NEOWISE infrared full-sky data. By analyzing tiny changes in infrared radiation, the AI sorted the objects into 10 classes. He found 1.5 million new potential objects.



    • Second place and $175,000 went to Ava Grace Cummings, 18, of Smithfield, NC, for creating a fruit fly model of STAC3 disorder, or Native American myopathy (a rare genetic muscle disease). She found that the common nettle herb, alone or combined with the experimental drug Tirasemtiv, improved movement in both adult flies and larvae.



    • Third place and $150,000 went to Owen Jianwen Zhang, 18, of Bellevue, WA, for solving a long-standing math problem about objects called 3-uniform hypergraphs. He proved a maximum value for how many 3-uniform hypergraphs can have similar structures but differing connections. Owen's results have applications in computer science.

    "Congratulations to the winners of this year's Regeneron Science Talent Search," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. "The remarkable creativity and dedication of these students bring renewed hope for our future. Driven by their ingenuity, these young scientists are developing groundbreaking solutions that have the potential to transform our world and propel society forward."

    The Regeneron Science Talent Search provides a national platform for high school seniors to showcase original, innovative STEM research that proposes novel solutions to real-world issues. Finalists are evaluated for their scientific rigor, originality, critical thinking, leadership potential and commitment to drive meaningful impact across crucial STEM fields.

    "The Science Talent Search changed my life. At my high school, STS winners were treated like star athletes, and I never imagined I would belong in such an amazing group of kids who were operating at a whole different level than I had ever seen," said George D. Yancopoulos, co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron and a 1976 Science Talent Search finalist and top winner. "The experience of competing in STS and being named a top winner gave me the confidence to devote my life to science. So, congratulations to this year's finalists and winners, you are America's best and brightest. I hope this moment inspires you to push boundaries, challenge assumptions and use your brilliance to change the world."

    Other top honors from the competition include:

    • Fourth Place: Logan Lee, 18, of Honolulu, HI received a $100,000 award for helping sterile male mosquitoes survive in the wild. These males are important in mosquito control. Logan improved their survival by giving them a transplant of wild mosquito bacteria. His transplant helped the sterile mosquitoes grow faster and survive better in the wild.



    • Fifth Place: Rivka Lipkovitz, 18, of San Francisco, CA received a $90,000 award for using statistical modeling to study U.S. voter ID laws. She found that presidential election turnout dropped by 2.4% in states that passed strict laws after 2008. Turnout for midterm elections increased. Knowing how laws affect turnout can help shape future policies.



    • Sixth Place: Melody Heeju Hong, 17, of Wantagh, NY received a $80,000 award for developing a powerful, flexible statistical model for mapping sites called trans-methylation quantitative trait loci (trans-mQTL) within the human genome. These sites are key to understanding the interplay between genes and environment in disease and aging.



    • Seventh Place: Kevin Shen, 18, of Olympia, WA received a $70,000 award for building a custom flight computer to control a 3D-printed airplane with oblique wings. These aircraft can be more fuel-efficient but are hard to control. His oblique-wing aircraft and flight computer improved flight efficiency by 9.2%.



    • Eighth Place: Minghao Zou, 18, of Santa Clara, CA received a $60,000 award for simulating protons to probe environments that produce subatomic particles called neutrinos. He created an algorithm mimicking extreme astrophysical conditions, such as electromagnetic and gravitational forces and interactions with nearby particles. He verified it using known cases of particle motion.



    • Ninth Place: Thanush Patlolla, 17, of Cary, NC received a $50,000 award for approximating the density of electrons using a finite nuclear model. Using a mathematical strategy called a density function, he created a model to map electrons in a nuclear simulation. The map increased the accuracy of energy distribution predictions by 0.6%.



    • Tenth Place: Ray Zhang, 17, of Chantilly, VA received a $40,000 award for studying how to better treat drug-resistant Fusarium fungal infections. Ray studied how the fungus builds sticky communities of cells that resist drug treatment. He also found that using a combination of drugs better controlled the fungus.



    • Akilan Sankaran, 17, of Albuquerque, NM was named the Seaborg Award winner and selected to speak on behalf of the Regeneron Science Talent Search Class of 2025. The 40 finalists chose Akilan as the student who best exemplifies their class and the legacy of nuclear chemist Glenn T. Seaborg, who won the Nobel Prize for Chemistry in 1951 and served on the Society's Board of Trustees for 30 years.

    All other finalists received $25,000. All 40 finalists join a distinguished group of Science Talent Search alumni, many of whom have gone on to achieve world-changing careers in STEM, with some earning esteemed honors, including the Nobel Prize, National Medal of Science, and MacArthur Fellowship. In total, Regeneron awarded $3.1 million in prizes, including $2,000 to each top scholar and their school.

    Learn more about Regeneron Science Talent Search at https://www.societyforscience.org/regeneron-sts/ and learn about all their research projects at our Virtual Public Showcase.

    For media resources, visit https://www.societyforscience.org/2025-regeneron-science-talent-search-media-kit

    About Society for Science

    Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its outreach and equity programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram and Snapchat (Society4Science).

    About Regeneron

    Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases and rare diseases.

    Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious disease, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most "community-minded" companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro-bono and matching gift programs. Our most significant philanthropic commitments are in the area of science education, including the Regeneron Science Talent Search and the Regeneron International Science and Engineering Fair (ISEF).

    For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

    Media Contacts

    Joseph Brown, Regeneron

    386-283-1323, [email protected]   

            

    Gayle Kansagor, Society for Science

    703-489-1131, [email protected]



    Primary Logo

    Get the next $REGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $REGN

    DatePrice TargetRatingAnalyst
    12/3/2025$767.00Overweight → Equal-Weight
    Morgan Stanley
    11/24/2025$798.00Buy
    Truist
    11/24/2025$255.00Buy
    HSBC Securities
    11/13/2025$650.00Sector Perform
    Scotiabank
    8/14/2025$890.00Buy
    Rothschild & Co Redburn
    6/30/2025Buy → Hold
    Argus
    5/30/2025$662.00Outperform → Sector Perform
    RBC Capital Mkts
    5/30/2025$580.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $REGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

    All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating Lynozyfic-based regimens in earlier lines of treatment Regeneron to host virtual ‘Regeneron Roundtable' investor event to dis

    12/7/25 4:30:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

    TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of a cash upfront and equity investment from Regeneron; companies to share worldwide development costs and future profits 50:50Collaboration combines Regeneron's long-standing expertise in genetics, genetic medicines and clinical development with Tessera's pioneering Gene WritingTM and non-viral delivery platforms TARRYTOWN, N.Y. and SOMERVILLE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., today announced

    12/1/25 7:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

    Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation, is now approved for patients across seven chronic, inflammatory diseases in the EU TARRYTOWN, N.Y. and PARIS, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) for the treatment o

    11/25/25 1:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Regeneron Pharma downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Regeneron Pharma from Overweight to Equal-Weight and set a new price target of $767.00

    12/3/25 8:30:10 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist resumed coverage on Regeneron Pharma with a new price target

    Truist resumed coverage of Regeneron Pharma with a rating of Buy and set a new price target of $798.00

    11/24/25 9:17:24 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HSBC Securities initiated coverage on Regeneron Pharma with a new price target

    HSBC Securities initiated coverage of Regeneron Pharma with a rating of Buy and set a new price target of $255.00

    11/24/25 8:21:03 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $REGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    EVP & General Mgr, Industrial Van Plew Daniel P covered exercise/tax liability with 2,552 shares, decreasing direct ownership by 11% to 21,673 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    12/11/25 4:34:24 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP Research Murphy Andrew J covered exercise/tax liability with 4,229 shares, decreasing direct ownership by 8% to 47,833 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    12/11/25 4:32:45 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP Commercial Mccourt Marion covered exercise/tax liability with 1,021 shares, decreasing direct ownership by 7% to 14,349 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    12/11/25 4:30:49 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

    5/20/22 3:11:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    SEC Filings

    View All

    SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.

    13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    11/7/25 4:55:01 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Regeneron Pharmaceuticals Inc.

    10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    10/28/25 6:56:36 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    10/28/25 6:50:40 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Financials

    Live finance-specific insights

    View All

    Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

    All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating Lynozyfic-based regimens in earlier lines of treatment Regeneron to host virtual ‘Regeneron Roundtable' investor event to dis

    12/7/25 4:30:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

    Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting Additional oral presentation spotlights data for odronextamab in combination with chemotherapy, without rituximab, as a frontline treatment for diffuse large B-cell lymphoma Other presentations span a broad range of hematologic conditions, including paroxysmal nocturnal hemoglobinuria and severe aplastic anemia Regeneron to host virtual ‘Regeneron Roundtable' investor event to discuss its multiple myeloma development program on Wednesday, December 10 at 8:30 a.m. ET TARRYTOWN, N.Y., Nov.

    11/13/25 7:00:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

    Proof-of-concept trials confirm robust anti-clotting effects for Regeneron's two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results consistent with prospective design of these antibodies to have distinct profiles – one to provide stronger anticoagulation and the other to have a lower risk of bleeding – potentially allowing physicians to tailor anticoagulant therapy for patients with different risk profiles Phase 3 trials in patients undergoing total knee replacement initiated as part of broad factor XI program evaluating the two antibodies across a range of patient populations and clinical settings Regeneron to host vir

    11/8/25 10:46:31 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Leadership Updates

    Live Leadership Updates

    View All

    Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

    TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days' Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the 2025 calendar year, enabling more patients to affordably access essential medicines that help protect their vision. "We are proud to support Good Days with this unprecedented philanthropic effort," said Leonard Schleifer, M.D., Ph.D.,

    6/24/25 7:30:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

    TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie

    1/30/24 7:00:41 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

    NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

    10/18/23 9:00:00 AM ET
    $AZN
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/13/24 5:12:22 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 6:19:03 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 9:49:31 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care